Shanghai Junshi Biosciences Coの収益Y / Y
Shanghai Junshi Biosciences Coの収益Y / Yは何ですか。
Shanghai Junshi Biosciences Co., Ltd.の収益Y / Yは-23.54%です。
収益Y / Yの定義は何ですか。
過去3年間の年間収益の伸びは、過去3年間で平均した1年間の収益成長率です。
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
OTCのセクタHealth Careにおける収益Y / Yの企業と比べるShanghai Junshi Biosciences Co
Shanghai Junshi Biosciences Coは何をしますか。
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Shanghai Junshi Biosciences Coと類似の収益y / y
- Qingdao Haier Biomedical Coの収益Y / Yは-23.64%です。
- Vanda Pharmaceuticals Incの収益Y / Yは-23.63%です。
- Principal Incの収益Y / Yは-23.61%です。
- 17 Education & Technologyの収益Y / Yは-23.58%です。
- Columbia , Incの収益Y / Yは-23.57%です。
- Heartland USAの収益Y / Yは-23.55%です。
- Shanghai Junshi Biosciences Coの収益Y / Yは-23.54%です。
- Yangarra Resourcesの収益Y / Yは-23.54%です。
- Amarin Corpの収益Y / Yは-23.53%です。
- GMR Infrastructureの収益Y / Yは-23.51%です。
- Eastern Treadsの収益Y / Yは-23.50%です。
- Brookfield Property Partners L.Pの収益Y / Yは-23.50%です。
- Mesoblastの収益Y / Yは-23.48%です。